LSA
TXG icon

L & S Advisors’s 10x Genomics TXG Stock Holding History

L & S Advisors’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-2,000
Closed -$392K – 381
2021
Q2 		$392K Hold
2,000
– – 0.04% 263
2021
Q1 		$362K Sell
2,000
-500
-20% -$86.3K 0.04% 278
2020
Q4 		$354K Buy
+2,500
New +$363K 0.04% 267

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return
MCAV
Meritech Capital Associates V Palo Alto, California $141M AUM 15.44% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

L & S Advisors's TXG Position: Q3 2021 in Review

L & S Advisors sold out of 10x Genomics (TXG) in Q3 2021, closing a stake of 2,000 shares — an estimated $392K sold.

L & S Advisors first reported a position in TXG in Q4 2020 and held it in 3 quarters. The position peaked at $392K in Q2 2021. 330 funds tracked by Wall St. Rank hold TXG as of Q3 2021.

  • L & S Advisors reported no remaining 10x Genomics position as of Q3 2021 after selling out during the quarter.
  • L & S Advisors sold 2,000 10x Genomics shares in Q3 2021, an estimated $392K.
  • L & S Advisors first reported a position in 10x Genomics in Q4 2020 and held it in 3 quarters.
  • L & S Advisors's 10x Genomics position peaked at $392K in Q2 2021.
  • 330 funds tracked by Wall St. Rank held 10x Genomics as of Q3 2021.

Based on L & S Advisors's 13F filing for Q3 2021, filed 9 Nov 2021.